One Step Nucleic Acid Amplification (OSNA) positive micrometastases and additional histopathological NSLN metastases: Results from a single institution over 53 months
Introduction
Sentinel lymph node biopsy has become a widely accepted procedure for axillary staging in clinically node negative breast cancer patients. However, the clinical significance and management of micrometastases on histopathological analysis of the sentinel lymph node is controversial.1, 2, 3, 4, 5 Recent large patient cohort studies with longer follow-up have shown differential prognostic implications for micrometastatic disease in the sentinel lymph node.6 As their results account for a particular method of SLN analysis, these data may not be applicable to all centres due to the variability in the method of the histopathological sentinel nodal analysis across different units.1
Recently, there is considerable interest in intra-operative molecular analysis of the sentinel lymph node by RT-LAMP due to its accuracy and applicability.7, 8 One Step Nucleic Acid Amplification (OSNA) is a highly sensitive, automated and rapid assay that analyses lymph nodes for metastases by detection and amplification of the mRNA of cytokeratin 19 (CK19), an epithelial marker in breast cancer cells.9 This technique potentially represents the accurate reflection of tumour burden, particularly those with micrometastatic disease who are unlikely to have histopathologically and/or immunohistochemically positive non-sentinel nodes after axillary lymph node dissection (ALND). ALND in these patients may only serve for staging rather than therapeutic purpose and therefore long-term data are needed to address the clinical relevance of molecular biological occult breast cancer in sentinel lymph nodes. Our unit has established the accuracy and histopathological concordance of OSNA in four, high volume, breast cancer centres10 and has adopted it in routine clinical practice since December 2008. As the first UK centre to introduce OSNA, we have reported the preliminary review of our data on SLN analysis by OSNA.49 In this study, we describe the rate of NSLN metastases for patients with molecular biological micrometastatic disease in the SLN and compare it with the patients with SLN macrometastatic disease.
Section snippets
Methods
Data were collected prospectively from introduction 01/12/2008 to 31/05/2013. Details of methods have been described elsewhere.49 All eligible patients were offered OSNA and none declined. All patients had clinically, sonographically and cytologically negative axillae.
Results
A total of 1008 patients had 2151 SLNs analysed with an average of two nodes per patient. 66% of the patients had negative SLN (n = 672) and 34% (n = 336) had positive sentinel nodes who had further axillary surgery. Of these, 45% (n = 152/336) had macrometastases, 40% (n = 136/336) had micrometastases and 15% (n = 48/336) had positive but inhibited results (now adjusted to a quantifiable result49). These results are similar to those reported previously.49 In addition, 8% (83/1008) of our
Discussion
This study presents an updated and in depth analysis of our data.49 There has been one other study reporting the incidence of NSLN metastases in molecular biologically positive micrometastases, in patients with DCIS.15 As expected, the majority of the patients were node negative. Overall in the SLN positive patients, macrometastases form a large part of the group as compared with micrometastases. Not all patients had positive NSLNs and again a differential rate in NSLN metastases is seen in the
Collaborators
The authors are grateful to the biomedical scientists and others in the pathology teams including the biomedical scientists: Mary Divers, Dallisay Ramirez, Anthony Quicho, Noranette Villena and the operating room staff led by Kathy Skilton.
Acknowledgements
The authors express their thanks to BUFFER (The Breast Unit Fund for Education and Research) and the Juniper Trust, both registered charities. There was no financial contribution from any commercial organisation. The authors declare no conflict of interest.
References (49)
- et al.
Significance of sentinel lymph node micro-metastases in human breast cancer
J Am Coll Surg
(2008) - et al.
Prognostic implications of isolated tumor cells and micro-metastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study
J Am Coll Surg
(2009) Prognostic importance of occult axillary lymph node micro-metastases from breast cancers
Lancet
(1990)- et al.
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group
Lancet
(1999) - et al.
The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer
Eur J Cancer
(2008) - et al.
Axillary node micro-metastases and breast cancer
Lancet
(1991) - et al.
A differential intra-operative molecular biological test for the detection of sentinel lymph node metastases in breast carcinoma. An extended experience from the first UK centre routinely offering the service in clinical practice
EJSO
(2014) - et al.
Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden
Ann Surg Oncol
(2010) - et al.
Micro-metastases or isolated tumor cells and the outcome of breast cancer
N Engl J Med
(2009) - et al.
One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients
Clin Cancer Res
(2007)
Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay
Clin Cancer Res
Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer
Int J Cancer
Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection
Ann Surg
Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement
J Clin Oncol
Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial
Semin Surg Oncol
Incidence and possible pathogenesis of sentinel node micrometastases in ductal carcinoma in situ of the breast detected using molecular whole lymph node assay
Br J Cancer
Prevalence of micrometastases and isolated tumor cells in the sentinel node in early stage breast cancer
Rev Esp Med Nucl Imagen Mol
Detection and significance of occult metastases in node-negative breast cancer
Br J Surg
Occult axillary node metastases in breast cancer are prognostically significant: results in 368 nodenegative patients with 20-year follow-up
J Clin Oncol
Immunohistochemically detected lymph-node micro-metastases in breast cancer and their correlation with prognostic factors
Breast J
Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients
Clin Cancer Res
Micro-metastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance
Br J Cancer
Prognostic significance of cytokeratin-positive breast cancer metastases
Mod Pathol
Cited by (5)
Socioeconomic inequalities in mammography screening in Spanish women aged 45 to 69
2018, Gaceta SanitariaDevelopment of a Colloidal Gold Immunochromatographic Strip for Rapid Detection of Cyfra 21-1 in Lymph Node Metastasis of Thyroid Cancer
2022, Frontiers in Bioengineering and BiotechnologyAxillary lymph node surgical treatment
2018, Translational Cancer ResearchOne-step nucleic acid amplification (OSNA): where do we go with it?
2017, International Journal of Clinical OncologyEvaluation of the Metasin assay for intraoperative assessment of sentinel lymph node metastases in breast cancer
2017, Journal of Clinical Pathology